Cancer pain and anxiety

Current Pain and Headache Reports

Volumn 7, Issue 4, 2003, Pages 249-261

  Thielking, Paul D ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BUSPIRONE; CARBAMAZEPINE; GABAPENTIN; HYDROXYZINE; LAMOTRIGINE; LORAZEPAM; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; PLACEBO; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ACUPUNCTURE; AKATHISIA; ALTERNATIVE MEDICINE; ANAMNESIS; ANXIETY DISORDER; BEHAVIOR; BEHAVIOR THERAPY; BODY WEIGHT DISORDER; CANCER PAIN; CANCER PATIENT; COGNITION; COGNITIVE DEFECT; COGNITIVE THERAPY; CONSTIPATION; DAILY LIFE ACTIVITY; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; EMOTIONALITY; EXTRAPYRAMIDAL SYNDROME; GASTROINTESTINAL DISEASE; GROUP THERAPY; HAMILTON SCALE; HANGOVER; HERBAL MEDICINE; HUMAN; HYPNOSIS; INCREASED APPETITE; INDIVIDUALIZATION; INTERVIEW; MALADJUSTMENT; MEDICAL DECISION MAKING; MEDITATION; MEMORY DISORDER; NAUSEA; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; PSYCHOMOTOR DISORDER; PSYCHOTHERAPY; RATING SCALE; RELAXATION TRAINING; REVIEW; SCREENING TEST; SEDATION; SEXUAL DYSFUNCTION; SLEEP DISORDER; SOMNOLENCE; SYMPTOM; TRANSCENDENTAL MEDITATION; URINE RETENTION; VISUAL IMPAIRMENT; XEROSTOMIA; ANXIETY; NEOPLASM; PAIN;

ANXIETY; HUMANS; NEOPLASMS; PAIN;

EID: 0042911715     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-003-0045-x     Document Type: Review

References (115)

1. International Association for the Study of Pain: http:/www.iasp-pain.org. Accessed January 10, 2003.
2. Ahles TA, Blanchard EB, Ruckdeschel JC: The multidimensional nature of cancer-related pain. Pain 1983, 17:277-278.
3. Holland, JC: Anxiety and cancer: the patient and the family. J Clin Psychiatry 1989, 50:20-25.
4. Pine DS: Anxiety disorders: clinical features. In Kaplan and Sadock's Comprehensive Textbook of Psychiatry, edn 7. Edited by Sadock BJ, Sadock VA. Philadelphia: Lippincott Williams & Wilkins; 2000:1476-1490.
5. Kessler RC, McGonagle KA, Zhao S, et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994, 51:8-19.
6. Bourdon KH, Rae DS, Locke BZ, et al.: Estimating the prevalence of mental disorders in U.S. adults from the epidemiologic catchment area survey. Public Health Rep 1992, 107:663-667.
7. Derogatis LR, Morrow GR, Fetting J, et al.: The prevalence of psychiatric disorders among cancer patients. JAMA 1983, 249:751-757.
8. Stark D, Kiely M, Smith A, et al.: Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 2002, 20:3137-3148.
9. Noyes R, Holt CS, Massie MJ: Anxiety Disorders. In Psychooncology. Edited by Holland JC. New York: Oxford University Press; 1998:548-563.
10. Portenoy RK, Miransky J, Thaler HT, et al.: Pain in ambulatory patients with lung or colon cancer. Cancer 1992, 70:1616-1624.
11. Ahles TA, Ruckdeschel JC, Blanchard EB: Cancer-related pain. I: prevalence in an outpatient setting as a function of stage of disease and type of cancer. J Psychosom Res 1984, 28:115-119.
12. Bresica FJ, Adler D, Gray G, et al.: Hospitalized advanced cancer patients: a profile. J Pain Symptom Manage 1990, 5:221-227.
13. Portenoy RK: Cancer pain: epidemiology and syndromes. Cancer 1989, 63:2298-2307.
14. Daut RL, Cleeland CS: The prevalence and severity of pain in cancer. Cancer 1982, 50:1913-1918.
15. Glover J, Dibble SL, Dodd MJ, Miaskowski C: Mood states of oncology outpatients: Does pain make a difference? J Pain Symptom Manage 1995, 10:120-128.
16. Casten RJ, Parmelee PA, Kleban MH, et al.: The relationships among anxiety, depression, and pain in a geriatric institutionalized sample. Pain 1995, 61:271-276.
17. Quick Reference to the Diagnostic Criteria from DSM-IV: Washington D.C.: American Psychiatric Association; 1994.
18. Tremblay A, Breitbart W: Psychiatric dimensions of palliative care. Neurol Clin 2001, 19:949-966.
19. Massie MJ, Holland JC: The cancer patients with pain: psychiatric complications and their management. J Pain Symptom Manage 1992, 7:99-109.
20. Stark DPH, House A: Anxiety in cancer patients. Br J Cancer 2000, 83:1261-1267.
21. Portenoy RK, Payne D, Jacobsen P: Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999, 81:129-134.
22. Bonaccorso S, Puzella A, Marino V, et al.: Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001, 105:45-55.
23. Schag CAC, Heinrich RL: Anxiety in medical situations: adult cancer patients. J Clin Psychol 1989, 45:20-27.
24. Maier W, Buller R, Philipp M, Heuser I: The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 1988, 14:61-68.
25. Carroll BT, Kathol RG, Noyes R, et al.: Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. Gen Hosp Psychiatry 1993, 15:69-74.
26. Lloyd-Williams M, Friedman T, Rudd N: An analysis of the validity of the Hospital Anxiety and Depression Scale as a screening tool in patients with advanced metastatic cancer. J Pain Symptom Manage 2001, 22:990-996.
27. Tamburini M: Health related quality of life measures in cancer. Ann Oncol 2001, 12 (suppl 3):S7-S10.
28. Jamison RN, Rock DL, Parris WCV: Empirically derived Symptom Checklist 90 subgroups of chronic pain patients: a cluster analysis. J Behav Med 1988, 11:147-158.
29. Stefanek ME, Derogatis LP, Shaw A: Psychological distress among oncology outpatients: prevalence and severity as measured with the Brief Symptom Inventory. Psychosomatics 1987, 28:530-539.
30. Benotsch EG, Lutgendorf SK, Wason D, et al.: Rapid anxiety assessment in medical patients: evidence for the validity of verbal anxiety ratings. Ann Behav Med 2000, 22:199-203.
31. Weisenberg M, Aviram O, Wolf Y, Raphaeli N: Relevant and irrelevant anxiety in the reaction to pain. Pain 1984, 20:371-383.
32. Strang P: Existential consequences of unrelieved cancer pain. Palliat Med 1997, 11:299-305.
33. Rhudy JL, Meagher MW: Fear and anxiety: divergent effects on human pain thresholds. Pain 2000, 84:65-75.
34. Janssen SA, Arntz A: Anxiety and pain: attentional and endorphinergic influences. Pain 1996, 66:145-150.
35. Janssen SA, Arntz A, Bouts S: Anxiety and pain: epinephrine-induced hyperalgesia and attentional influences. Pain 1998, 76:309-316.
36. Arntz A, Dreessen L De Jong P: The influence of anxiety on pain: attentional and attributional mediators. Pain 1994, 56:307-314.
37. Crombez G, Vlaeyen JWS, Heuts P, Lysens R: Pain-related fear is more disabling than pain itself: evidence on the role of pain-related fear in chronic back pain disability. Pain 1999, 80:329-339.
38. Krystal JH, D'Souza C, Sanacora G, et al.: Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. Med Clin North Am 2001, 85:559-574.
39. Gorman JM, Kent JM, Sullivan GM, Coplan JD: Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000, 157:493-505.
40. Charney DS, Deutch A: A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit Revi Neurobiol 1996, 10:419-446.
41. Regan JM, Peng P: Neurophysiology of cancer pain. Cancer Control 2000, 7:111-119.
42. Melzack R: From the gate to the neuromatrix. Pain 1999, Suppl 6:S121-S126.
43. NIH Technology Assessment Panel on integration of behavioral and relaxation approaches in the treatment of chronic pain and insomnia. JAMA 1996, 276:313-318.
44. Melzack R: Pain: an overview. Acta Anaesthesiol Scand 1999, 43:880-884.
45. Ploghaus A, Narain C, Bechmann CF, et al.: Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci 2001, 21:9896-9903.
46. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain 1997, 13:116-137.
47. Breitbart W: Psychotropic adjuvant analgesics for cancer pain. Psychooncology 1992, 1:133-145.
48. Berney A, Stiefel F, Mazzocato C, Buclin T: Psychopharmacology in supportive care of cancer: a review for the clinician III. antidepressants. Support Care Cancer 2000, 8:278-286.
49. Grond S, Zech D, Diefenbach C, et al.: Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain 1996, 64:107-114.
50. Brawman-Mintzer O: Pharmacologic treatment of generalized anxiety disorder. Psychiatr Clin North Am 2001, 24:119-133.
51. Holland JC, Morrow GR, Schmale A, et al.: A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol 1991, 6:1004-1011.
52. Fernandez F, Adams F, Holmes VF: Analgesic effect of alprazolam in patients with chronic, organic pain of malignant origin. J Clin Psychopharmacol 1987, 7:167-169.
53. Wald TG, Kathol RG, Noyes R, et al.: Rapid relief of anxiety in cancer patients with both alprazolam and placebo. Psychosomatics 1993, 34:324-332.
54. Kishore-Kumar R, Schafer SC, Lawlor BA, et al.: Single doses of the serotonin agonist buspirone and m-chlorophenylpiperazine do not relieve neuropathic pain. Pain 1989, 37:223-227.
55. Stiefel F, Berney A, Mazzocato C: Psychopharmacology in supportive care in cancer: a review for the clinician I. benzodiazepines. Support Care Cancer 1999, 7:379-385.
56. Max MB, Schafer SC, Culnane M, et al.: Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988, 38:1427-1432.
57. Reddy S, Patt RB: The benzodiazepines as adjuvant analgesics. J Pain Symptom Manage 1994, 9:510-514.
58. Stahl SM: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, edn 2. Cambridge: Cambridge University Press; 2000.
59. Rickels K, Downing R, Schweizer E, Hassman H: Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry 1993, 50:884-895.
60. Rocca P, Fonzo V, Scotta M, et al.: Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997, 95:444-450.
61. Davidson JRT: Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001, 62 (suppl 11):46-50.
62. Bakker A, van Baldom AJLM, Spinhoven P: SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand 2002, 106:163-167.
63. Sindrup SH, Gram LF, Brosen K, et al.: The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990, 42:135-144.
64. Max MB, Lynch SA, Muir J, et al.: The effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992, 326:1250-1256.
65. Gelenberg AJ, Lydiard RB, Rudolph RL, et al.: Efficacy of venlafaxine XR capsules in nondepressed outpatients with generalized anxiety disorder. JAMA 2000, 283:3082-3088.
66. Tasmuth T, Hartel B, Kalso E: Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002, 6:17-24.
67. Trivedi MH, Rush AJ, Carmody TJ, et al.: Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry 2001, 62:776-781.
68. Semenchuk MR, Sherman S, Davis B: Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001, 57:1583-1588.
69. Theobald DE, Kirsh KL, Holtsclaw E, et al.: An open-label, crossover trial of mirtazapine in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002, 23:442-447.
70. Goodnick PJ, Puig A, DeVane CL, Freund BV: Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry 1999, 60:446-448.
71. Fawcett J, Barkin R: A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998, 59:123-127.
72. DeMartinis NA, Schweizer E, Rickels K: An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996, 57:245-248.
73. Saper JR, Lake AE, Tepper SJ: Nefazodone for chronic daily headache prophylaxis: an open label study. Headache 2001, 41:465-474.
74. Rickels K, Weisman K, Norstad N, et al.: Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982, 43:81-86.
75. Buclin T, Mazzocato C, Berney A, Stiefel F: Psychopharmacology in supportive care of cancer: a review for the clinician IV. Other psychotropic agents. Support Care Cancer 2001, 9:213-222.
76. Llorca PM, Spadone C, Sol O, et al.: Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry 2002, 63:1020-1027.
77. Rumore MM, Schlichting DA: Clinical efficacy of antihistamines as analgesics. Pain 1986, 25:7-22.
78. Glazier HS: Potentiation of pain relief with hydroxyzine: a therapeutic myth? DICP 1990, 24:484-488.
79. Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL: Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry 1998, 59:480-401.
80. Pollack MH: Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 1998, 155:992-993.
81. Tremont-Lukats IW, Megeff C, Backonja MM: Anticonvulsants for neuropathic pain syndromes. Drugs 2000, 60:1029-1052.
82. Backonja M, Beydoun A, Edwards KR, et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 1998, 280:1831-1836.
83. Field MJ, Oles RJ, Singh L: Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol 2001, 32:1-4.
84. Mazzocato C, Stiefel F, Buclin T, Berney A: Psychopharmacology in supportive care of cancer: a review for the clinician II. neuroleptics. Support Care Cancer 2000, 8:89-97.
85. Patt RB, Proper G, Reddy S: The neuroleptics as adjuvant analgesics. J Pain Symptom Manage 1994, 9:446-453.
86. Khojainova N, Santiago-Palma J, Kornick C, et al.: Olanzapine in the management of cancer pain. J Pain Symptom Manage 2002, 23:346-350.
87. Mintzer J, Faison W, Street JS, et al.: Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. Int J Geriatr Psychiatry 2001, 16:S71-S77.
88. Kaplan M: Atypical antipsychotics for treatment of mixed depression and anxiety. J Clin Psychiatry 2000, 61:388-389.
89. Twillman RK, Manetto C: Concurrent psychotherapy and pharmacotherapy in the treatment of depression and anxiety in cancer patients. Psychooncology 1998, 7:285-290.
90. Fawzy I, Fawzy MD, Arndt LA, Pasnau RO: Critical review of psychosocial interventions in cancer care. Arch Gen Psychiatry 1995, 52:100-113.
91. Borkovec TD, Ruscio AM: Psychotherapy for generalized anxiety disorder. J Clin Psychiatry 2001, 62(suppl 11):37-42.
92. Postone N. Psychotherapy with cancer patients. Am J Psychother 1998, 52:412-423.
93. Yalom ID: Existential Psychotherapy. New York: Basic Books; 1980.
94. Otis-Green S, Sherman R, Perez M, Baird P: An integrated psychosocial-spiritual model for cancer pain management. Cancer Practice 2002, 10(suppl 1):58-64.
95. Spiegel D, Bloom JR, Yalom I: Group support for patients with metastatic cancer. Arch Gen Psychiatry 1981, 38:527-533.
96. Cain EN, Kohorn EI, Quinlan DM, et al.: Psychosocial benefits of a cancer support group. Cancer 1986, 57:183-189.
97. Classen C, Butler LD, Koopman C, et al.: Supportive-expressive group therapy and distress in patients with metastatic breast cancer. Arch Gen Psychiatry 2001, 58:494-501.
98. National Center for Complementary and Alternative Medicine. http://nccam.nih.gov. Accessed January 12, 2003.
99. Richardson MA, Sanders T, Palmer JL, et al.: Complementary/Alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000, 18:2505-2514.
100. Genuis ML: The use of hypnosis in helping cancer patients control anxiety, pain and emesis: a review of recent empirical studies. Am J Clin Hypn 1995, 37:316-325.
101. Barrows KA, Jacobs BP: Mind-Body Medicine: an introduction and review of the literature. Med Clin North Am 2002, 86:11-30.
102. Speca M, Carlson LE, Goody E, Angen M: A randomized, wait-list controlled clinical trial: the effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosom Med 2000, 62:613-622.
103. Reibel DK, Greeson JM, Brainard GC, Rosenzweig S: Mindfulness-based stress reduction and health-related quality of life in a heterogeneous patient population. Gen Hosp Psychiatry 2001, 23:183-192.
104. Kabat-Zinn J, Lipworth L, Burney R: The clinical use of mindfulness meditation for the self-regulation of chronic pain. J Behav Med 1985, 8:163-190.
105. Benson H: Timeless Healing. New York: Fireside; 1996.
106. NIH Consensus Conference: Acupuncture. JAMA 1998, 280:1518-1524.
107. Meng FQ, Luo HC, Halbreich: Concepts, techniques, and clinical applications of acupuncture. Psychiatr Ann 2002, 32:45-49.
108. Mischoulon D: The herbal anxiolytics Kava and Valerian for anxiety and insomnia. Psychiatr Ann 2002, 32:55-60.
109. Turner JG, Clark AJ, Gauthier GK, Williams M: The effect of therapeutic touch on pain and anxiety in burn patients. J Adv Nurs 1998, 28:10-20.
110. Quill TE, Byock IR: Responding to intractable terminal suffering: the role of terminal sedation and voluntary refusal of food and fluids. Ann Intern Med 2000, 132:408-414.
111. Quill TE, Lo B, Brock DW: Palliative options of last resort: a comparison of voluntary stopping eating and drinking, terminal sedation, physician assisted suicide, and voluntary active euthanasia. JAMA 1997, 278:2099-2104.
112. Chater S, Viola R, Paterson J, Jarvis V: Sedation for intractable distress in the dying: a survey of experts. Palliat Med 1998, 12:255-269.
113. Fainsinger RL, Waller A, Bercovici M, et al.: A multicenter international study of sedation for uncontrolled symptoms in terminally ill patients. Palliat Med 2000, 14:257-265.
114. Covan JD, Walsh D: Terminal sedation in palliative medicine: definition and review of the literature. Support Care Cancer 2001, 9:403-407.
115. Albers LJ, Hahn RK, Reist C: Handbook of Psychiatric Drugs. Laguna Hills, CA: Current Clinical Strategies Publishing; 1998-1999.